Changes in skeletal muscle loss between cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non-small cell lung cancer
Not Applicable
- Conditions
- Patients with pathologically proven Non-small cell lung cancer stage4
- Registration Number
- JPRN-UMIN000027812
- Lead Sponsor
- St. Marianna University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Muscle mass was measured with a single cross-sectional area of the muscle at the third lumber vertebra (L3MA). To estimate skeletal muscle changes during chemotherapy, we set the following L3 muscle index (L3SMI) ratio: post L3SMI / pre L3SMI.
- Secondary Outcome Measures
Name Time Method